Table 1. Clinical characteristics of patients.
| Patient characteristics | Exploratory set | Validation set 1 | Validation set 2 |
|---|---|---|---|
| N = 41 | N = 28 | N = 24 | |
| Gender | |||
| Male | 30 (73.2%) | 17 (60.7%) | 15 (62.5%) |
| Female | 11 (26.8%) | 11 (39.3%) | 9 (37.5%) |
| Age | |||
| Median | 54 | 61 | 68 |
| Range | 54,8 (31–72) | 60 (48–76) | 66 (45–81) |
| Chemotherapy regimen | |||
| Cetuximab irinotecan | 38 | 13 | 0 |
| Cetuximab FOLFOX, FOLFIRI | 0 | 1 | 0 |
| Cetuximab FOLFIRI | 2 | 12 | 0 |
| Cetuximab FOLFOX | 0 | 1 | 0 |
| Cetuximab deGramont | 0 | 1 | 0 |
| Cetuximab XELIRI | 1 | 0 | 0 |
| Panitumumab | 0 | 0 | 22 |
| Panitumumab FOLFIRI | 0 | 0 | 2 |
| Number of treatment lines before anti-EGFR therapy | |||
| Median | 3 | 2 | 1 |
| Range | (2–5) | (2–4) | (1–3) |
| Response according to RECIST criteria | |||
| Complete response | 6 | 0 | 1 |
| Partial response | 13 | 6 | 4 |
| Stable disease | 2 | 8 | 6 |
| Progressive disease | 20 | 14 | 13 |